Flag of the European Union EU Clinical Trials Register Help

Clinical trials for EuroFlow

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: EuroFlow. Displaying page 1 of 1.
    EudraCT Number: 2019-004401-27 Sponsor Protocol Number: OMC01/19 Start Date*: 2020-04-20
    Sponsor Name:Oslo University Hospital, Department of Hematology
    Full Title: The REMNANT (RElapse from Mrd Negativity As iNdication for Treatment) study
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) LT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004425-23 Sponsor Protocol Number: OMC02/20 Start Date*: 2021-01-28
    Sponsor Name:Oslo University Hospital, Department of Hematology
    Full Title: A Phase 2, single arm, open label, multicenter study to assess minimal residual disease after isatuximab in combination with bortezomib and lenalidomide with minimal dexamethasone in patients with ...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003092-18 Sponsor Protocol Number: TIKTAC Start Date*: 2021-05-12
    Sponsor Name:Medical University Innsbruck
    Full Title: Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure - “Time Is Kidney in the Treatment of myelomA Cast n...
    Medical condition: Multiple Myeloma: cohort 1: dialysis dependent patients; cohort 2: patients not dialysis dependent
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000586-72 Sponsor Protocol Number: NMSG#25/16 Start Date*: 2017-10-10
    Sponsor Name:Oslo University Hospital
    Full Title: KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DK (Trial now transitioned) SE (Prematurely Ended) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-004207-32 Sponsor Protocol Number: TIKTAC-2-Trial Start Date*: 2023-04-20
    Sponsor Name:Medical University Innsbruck, Internal Medicine V
    Full Title: Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure NOT requiring dialysis - “Time Is Kidney in the Trea...
    Medical condition: Multiple Myeloma: Patients with MM are frequently diagnosed primarily due to renal failure. Patients with renal failure have a poor prognosis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002245-29 Sponsor Protocol Number: BB2121-MM-001 Start Date*: 2018-10-02
    Sponsor Name:Celgene Corporation
    Full Title: A phase 2, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma
    Medical condition: Relapsed and Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10067095 Multiple myeloma progression LLT
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000264-28 Sponsor Protocol Number: bb2121-MM-002 Start Date*: 2018-10-19
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Multi-cohort, Open-label, Multi-center Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multi...
    Medical condition: Relapsed and Refractory Multiple Myeloma and High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    20.0 100000004864 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) FR (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001023-38 Sponsor Protocol Number: bb2121-MM-003 Start Date*: 2019-05-13
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (Rrmm) (...
    Medical condition: Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of com...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    20.0 100000004864 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Completed) DE (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001729-26 Sponsor Protocol Number: CC-5013-MM-026 Start Date*: 2014-03-25
    Sponsor Name:Celgene Corporation
    Full Title: Phase 3b, Randomized Trial of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® (Bortezomib) Induction Therapy in Newly Diagnosed Multiple Myeloma
    Medical condition: Newly diagnosed multiple myeloma (NDMM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) IT (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 12:41:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA